PDCD1 and melanoma: In addition, based on the common subtype comparison analysis between two CRDC groups and melanoma samples with the information of immunotherapy reaction (Roh et al., 2017; Chen et al., 2021), we could infer that patients with low CRDC risk were more likely to respond to anti-PD1 therapy (Bonferroni-corrected p = 0.044), yet high CRDC group may be resistant to this form of treatment (Nominal p = 0.042, Figure 7J).